表紙
市場調査レポート

前立腺癌:パイプライン製品の分析

Prostate Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232770
出版日 ページ情報 英文 1555 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
前立腺癌:パイプライン製品の分析 Prostate Cancer - Pipeline Review, H1 2016
出版日: 2016年06月28日 ページ情報: 英文 1555 Pages
概要

前立腺癌は前立腺より発症する癌の一種で、男性、特に高齢の男性が罹患します。主な症状として、排尿時のトラブルや尿を出す力の低下、血尿、腰・臀部・大腿部などの痛みなどが挙げられます。疾病素質には年齢や家族歴、肥満症などが含まれています。主な治療法には外科手術や化学療法、放射線治療などがあります。

当レポートでは、世界各国での前立腺癌治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

前立腺癌の概要

治療薬の開発

前立腺癌:企業で開発中の治療薬

前立腺癌:大学/機関で研究中の治療薬

前立腺癌:パイプライン製品の概況

前立腺癌:企業で開発中の製品

前立腺癌:大学/機関で研究中の製品

前立腺癌の治療薬開発に従事している企業

前立腺癌:治療薬の評価

薬剤プロファイル

前立腺癌:休止中のプロジェクト

前立腺癌:開発が中止された製品

前立腺癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7952IDB

Summary

Global Markets Direct's, 'Prostate Cancer - Pipeline Review, H1 2016', provides an overview of the Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
  • The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer Overview
  • Therapeutics Development
  • Prostate Cancer - Therapeutics under Development by Companies
  • Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Prostate Cancer - Pipeline Products Glance
  • Prostate Cancer - Products under Development by Companies
  • Prostate Cancer - Products under Investigation by Universities/Institutes
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Drug Profiles
  • Prostate Cancer - Dormant Projects
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Prostate Cancer, H1 2016
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Development by Companies, H1 2016 (Contd..20)
  • Number of Products under Development by Companies, H1 2016 (Contd..21)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Development by Companies, H1 2016 (Contd..29)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Prostate Cancer - Pipeline by 4SC AG, H1 2016
  • Prostate Cancer - Pipeline by AB Science SA, H1 2016
  • Prostate Cancer - Pipeline by AbbVie Inc., H1 2016
  • Prostate Cancer - Pipeline by Acino International AG, H1 2016
  • Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016
  • Prostate Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Prostate Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016
  • Prostate Cancer - Pipeline by Advantagene, Inc., H1 2016
  • Prostate Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Prostate Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Akshaya Bio Inc., H1 2016
  • Prostate Cancer - Pipeline by Alchemia Limited, H1 2016
  • Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Prostate Cancer - Pipeline by Almac Discovery Limited, H1 2016
  • Prostate Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Prostate Cancer - Pipeline by American Gene Technologies International Inc., H1 2016
  • Prostate Cancer - Pipeline by Amgen Inc., H1 2016
  • Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Prostate Cancer - Pipeline by AndroScience Corporation, H1 2016
  • Prostate Cancer - Pipeline by AnGes MG, Inc., H1 2016
  • Prostate Cancer - Pipeline by AntiCancer, Inc., H1 2016
  • Prostate Cancer - Pipeline by Antigen Express, Inc., H1 2016
  • Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H1 2016
  • Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016
  • Prostate Cancer - Pipeline by Apcure SAS, H1 2016
  • Prostate Cancer - Pipeline by Aphios Corporation, H1 2016
  • Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2016
  • Prostate Cancer - Pipeline by Aptose Biosciences Inc., H1 2016
  • Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2016
  • Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by ArQule, Inc., H1 2016
  • Prostate Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Arvinas, Inc., H1 2016
  • Prostate Cancer - Pipeline by Asana BioSciences, LLC, H1 2016
  • Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Prostate Cancer - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Prostate Cancer - Pipeline by Avipep Pty Ltd, H1 2016
  • Prostate Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Prostate Cancer - Pipeline by Baxalta Incorporated, H1 2016
  • Prostate Cancer - Pipeline by Bayer AG, H1 2016
  • Prostate Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016
  • Prostate Cancer - Pipeline by BHR Pharma, LLC, H1 2016
  • Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Prostate Cancer - Pipeline by Bionature E.A. Ltd., H1 2016
  • Prostate Cancer - Pipeline by Biotest AG, H1 2016
  • Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Blirt S.A., H1 2016
  • Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Prostate Cancer - Pipeline by Camurus AB, H1 2016
  • Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Prostate Cancer - Pipeline by CEL-SCI Corporation, H1 2016
  • Prostate Cancer - Pipeline by Celgene Corporation, H1 2016
  • Prostate Cancer - Pipeline by CellCentric Ltd, H1 2016
  • Prostate Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Prostate Cancer - Pipeline by Celprogen, Inc., H1 2016
  • Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H1 2016
  • Prostate Cancer - Pipeline by CohBar, Inc., H1 2016
  • Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2016
  • Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016
  • Prostate Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Crescendo Biologics Limited, H1 2016
  • Prostate Cancer - Pipeline by CureVac GmbH, H1 2016
  • Prostate Cancer - Pipeline by CytoVac A/S, H1 2016
  • Prostate Cancer - Pipeline by CZ BioMed Corp, H1 2016
  • Prostate Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Prostate Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
  • Prostate Cancer - Pipeline by DexTech Medical AB, H1 2016
  • Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016
  • Prostate Cancer - Pipeline by DormaTarg, Inc., H1 2016
  • Prostate Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2016
  • Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H1 2016
  • Prostate Cancer - Pipeline by EndoCeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Endocyte, Inc., H1 2016
  • Prostate Cancer - Pipeline by EntreChem, S.L., H1 2016
  • Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H1 2016
  • Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by ESSA Pharma Inc, H1 2016
  • Prostate Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Evgen Pharma Plc, H1 2016
  • Prostate Cancer - Pipeline by Exonate Limited, H1 2016
  • Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Prostate Cancer - Pipeline by Ferring International Center S.A., H1 2016
  • Prostate Cancer - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Prostate Cancer - Pipeline by Fountain Biopharma Inc., H1 2016
  • Prostate Cancer - Pipeline by Fujifilm Corporation, H1 2016
  • Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Genelux Corporation, H1 2016
  • Prostate Cancer - Pipeline by Genentech, Inc., H1 2016
  • Prostate Cancer - Pipeline by Genmab A/S, H1 2016
  • Prostate Cancer - Pipeline by GenSpera, Inc., H1 2016
  • Prostate Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2016
  • Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Prostate Cancer - Pipeline by GlycoMimetics, Inc., H1 2016
  • Prostate Cancer - Pipeline by GP Pharm, S.A., H1 2016
  • Prostate Cancer - Pipeline by GTx, Inc., H1 2016
  • Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
  • Prostate Cancer - Pipeline by Hybrigenics S.A., H1 2016
  • Prostate Cancer - Pipeline by IC-MedTech, Inc., H1 2016
  • Prostate Cancer - Pipeline by Ideaya Biosciences, Inc., H1 2016
  • Prostate Cancer - Pipeline by IGF Oncology, LLC., H1 2016
  • Prostate Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Prostate Cancer - Pipeline by Immuneed AB, H1 2016
  • Prostate Cancer - Pipeline by Immunocore Limited, H1 2016
  • Prostate Cancer - Pipeline by ImmunoFrontier, Inc., H1 2016
  • Prostate Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Immupharma Plc, H1 2016
  • Prostate Cancer - Pipeline by Incanthera Ltd., H1 2016
  • Prostate Cancer - Pipeline by Incuron, LLC, H1 2016
  • Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2016
  • Prostate Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Io Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Ipsen S.A., H1 2016
  • Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Prostate Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Prostate Cancer - Pipeline by Jyant Technologies, Inc., H1 2016
  • Prostate Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Kite Pharma, Inc., H1 2016
  • Prostate Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Prostate Cancer - Pipeline by Kura Oncology, Inc., H1 2016
  • Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Prostate Cancer - Pipeline by Lidds AB, H1 2016
  • Prostate Cancer - Pipeline by Luye Pharma Group Ltd., H1 2016
  • Prostate Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Prostate Cancer - Pipeline by Mallinckrodt Plc, H1 2016
  • Prostate Cancer - Pipeline by MaxiVAX SA, H1 2016
  • Prostate Cancer - Pipeline by Meabco A/S, H1 2016
  • Prostate Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016

List of Figures

  • Number of Products under Development for Prostate Cancer, H1 2016
  • Number of Products under Development for Prostate Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top